{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T12:34:50Z","timestamp":1763382890902,"version":"3.45.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00198-025-07696-7","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:47:39Z","timestamp":1758361659000},"page":"2331-2336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of standard versus cyclic teriparatide and denosumab treatment on trabecular bone score: a post-hoc analysis of a randomized clinical trial"],"prefix":"10.1007","volume":"36","author":[{"given":"Alexander S.","family":"Dash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Hind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Hans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeri","family":"Nieves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4554-6616","authenticated-orcid":false,"given":"Felicia","family":"Cosman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"7696_CR1","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"},{"key":"7696_CR2","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab 104:1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"key":"7696_CR3","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.eprac.2024.01.014","volume":"30","author":"F Cosman","year":"2024","unstructured":"Cosman F, Langdahl B, Leder BZ (2024) Treatment sequence for osteoporosis. Endocr Pract 30:490\u2013496","journal-title":"Endocr Pract"},{"key":"7696_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists\/american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:1\u201346","journal-title":"Endocr Pract"},{"key":"7696_CR5","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1210\/jc.2015-1715","volume":"100","author":"F Cosman","year":"2015","unstructured":"Cosman F, Nieves JW, Zion M, Garrett P, Neubort S, Dempster D, Lindsay R (2015) Daily or cyclical teriparatide treatment in women with osteoporosis on no prior therapy and women on alendronate. J Clin Endocrinol Metab 100:2769\u20132776","journal-title":"J Clin Endocrinol Metab"},{"key":"7696_CR6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ et al (2016) Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 316:722\u2013733","journal-title":"JAMA"},{"key":"7696_CR7","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","volume":"99","author":"BZ Leder","year":"2014","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, Lee H, Neer RM (2014) Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial. J Clin Endocrinol Metab 99:1694\u20131700","journal-title":"J Clin Endocrinol Metab"},{"key":"7696_CR8","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","volume":"16","author":"F Cosman","year":"2001","unstructured":"Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R (2001) Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 16:925\u2013931","journal-title":"J Bone Miner Res"},{"key":"7696_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jbmr.3641","volume":"34","author":"ML Bouxsein","year":"2019","unstructured":"Bouxsein ML, Eastell R, Lui LY et al (2019) Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34:632\u2013642","journal-title":"J Bone Miner Res"},{"key":"7696_CR10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","volume":"8","author":"DM Black","year":"2020","unstructured":"Black DM, Bauer DC, Vittinghoff E et al (2020) Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol 8:672\u2013682","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7696_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jbmr.4433","volume":"37","author":"R Eastell","year":"2022","unstructured":"Eastell R, Vittinghoff E, Lui LY et al (2022) Validation of the surrogate threshold effect for change in bone mineral density as a surrogate endpoint for fracture outcomes: the FNIH-ASBMR SABRE project. J Bone Miner Res 37:29\u201335","journal-title":"J Bone Miner Res"},{"key":"7696_CR12","doi-asserted-by":"publisher","first-page":"990","DOI":"10.4158\/EP151019.RA","volume":"22","author":"M Pawlowska","year":"2016","unstructured":"Pawlowska M, Bilezikian JP (2016) Beyond Dxa: advances in clinical applications of new bone imaging technology. Endocr Pract 22:990\u2013998","journal-title":"Endocr Pract"},{"key":"7696_CR13","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/jbmr.2176","volume":"29","author":"BC Silva","year":"2014","unstructured":"Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, McCloskey EV, Kanis JA, Bilezikian JP (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res 29:518\u2013530","journal-title":"J Bone Miner Res"},{"key":"7696_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s12020-021-02806-x","volume":"74","author":"E Shevroja","year":"2021","unstructured":"Shevroja E, Cafarelli FP, Guglielmi G, Hans D (2021) DXA parameters, trabecular bone score (TBS) and bone mineral density (BMD), in fracture risk prediction in endocrine-mediated secondary osteoporosis. Endocrine 74:20\u201328","journal-title":"Endocrine"},{"key":"7696_CR15","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/jbmr.499","volume":"26","author":"D Hans","year":"2011","unstructured":"Hans D, Goertzen AL, Krieg MA, Leslie WD (2011) Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res 26:2762\u20132769","journal-title":"J Bone Miner Res"},{"key":"7696_CR16","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s00198-014-2761-y","volume":"25","author":"WD Leslie","year":"2014","unstructured":"Leslie WD, Johansson H, Kanis JA, Lamy O, Oden A, McCloskey EV, Hans D (2014) Lumbar spine texture enhances 10-year fracture probability assessment. Osteoporos Int 25:2271\u20132277","journal-title":"Osteoporos Int"},{"key":"7696_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jocd.2017.05.007","volume":"20","author":"JN Tsai","year":"2017","unstructured":"Tsai JN, Jiang LA, Lee H, Hans D, Leder BZ (2017) Effects of teriparatide, denosumab, or both on spine trabecular microarchitecture in DATA-switch: a randomized controlled trial. J Clin Densitom 20:507\u2013512","journal-title":"J Clin Densitom"},{"key":"7696_CR18","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00198-014-2703-8","volume":"25","author":"C Senn","year":"2014","unstructured":"Senn C, Gunther B, Popp AW, Perrelet R, Hans D, Lippuner K (2014) Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study. Osteoporos Int 25:1945\u20131951","journal-title":"Osteoporos Int"},{"key":"7696_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00198-017-4304-9","volume":"29","author":"JP Bilezikian","year":"2018","unstructured":"Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D (2018) Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial. Osteoporos Int 29:323\u2013328","journal-title":"Osteoporos Int"},{"key":"7696_CR20","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/jbmr.2822","volume":"31","author":"DW Dempster","year":"2016","unstructured":"Dempster DW, Cosman F, Zhou H, Nieves JW, Bostrom M, Lindsay R (2016) Effects of daily or cyclic teriparatide on bone formation in the iliac crest in women on no prior therapy and in women on alendronate. J Bone Miner Res 31:1518\u20131526","journal-title":"J Bone Miner Res"},{"key":"7696_CR21","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"7696_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/jbmr.3850","volume":"35","author":"F Cosman","year":"2020","unstructured":"Cosman F, McMahon D, Dempster D, Nieves JW (2020) Standard versus cyclic Teriparatide and Denosumab treatment for osteoporosis: a randomized trial. J Bone Miner Res 35:219\u2013225","journal-title":"J Bone Miner Res"},{"key":"7696_CR23","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00198-023-06817-4","volume":"34","author":"E Shevroja","year":"2023","unstructured":"Shevroja E, Reginster JY, Lamy O et al (2023) Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. Osteoporos Int 34:1501\u20131529","journal-title":"Osteoporos Int"},{"key":"7696_CR24","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/jbmr.2734","volume":"31","author":"EV McCloskey","year":"2016","unstructured":"McCloskey EV, Oden A, Harvey NC et al (2016) A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 31:940\u2013948","journal-title":"J Bone Miner Res"},{"key":"7696_CR25","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/jbmr.4764","volume":"38","author":"F Cosman","year":"2023","unstructured":"Cosman F, Hans D, Shevroja E, Wang Y, Mitlak B (2023) Effect of abaloparatide on bone microarchitecture assessed by trabecular bone score in women with osteoporosis: post hoc analysis of ACTIVE and ACTIVExtend. J Bone Miner Res 38:464\u2013470","journal-title":"J Bone Miner Res"},{"key":"7696_CR26","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32:1291\u20131296","journal-title":"J Bone Miner Res"},{"key":"7696_CR27","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28:1723\u20131732","journal-title":"Osteoporos Int"},{"key":"7696_CR28","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33:190\u2013198","journal-title":"J Bone Miner Res"},{"key":"7696_CR29","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","volume":"37","author":"F Cosman","year":"2022","unstructured":"Cosman F, Huang S, McDermott M, Cummings SR (2022) Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Miner Res 37:2112\u20132120","journal-title":"J Bone Miner Res"},{"key":"7696_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jocd.2023.01.001","volume":"26","author":"WD Leslie","year":"2023","unstructured":"Leslie WD, Hans D, Silva BC (2023) Fracture prediction from trabecular bone score is unaffected by anti-resorptive treatment: a registry-based cohort study. J Clin Densitom 26:10\u201315","journal-title":"J Clin Densitom"},{"key":"7696_CR31","doi-asserted-by":"publisher","first-page":"e1534","DOI":"10.1210\/clinem\/dgad724","volume":"109","author":"F Bioletto","year":"2024","unstructured":"Bioletto F, Barale M, Maiorino F, Pusterla A, Fraire F, Arvat E, Ghigo E, Procopio M (2024) Trabecular bone score as a marker of skeletal fragility across the spectrum of chronic kidney disease: a systematic review and meta-analysis. J Clin Endocrinol Metab 109:e1534\u2013e1543","journal-title":"J Clin Endocrinol Metab"},{"key":"7696_CR32","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/jbmr\/zjae073","volume":"39","author":"WD Leslie","year":"2024","unstructured":"Leslie WD, Binkley N, Schousboe JT, Silva BC, Hans D (2024) Effect of abdominal tissue thickness on trabecular bone score and fracture risk in adults with diabetes: the Manitoba BMD registry. J Bone Miner Res 39:877\u2013884","journal-title":"J Bone Miner Res"},{"key":"7696_CR33","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00198-020-05458-1","volume":"31","author":"C Rampersad","year":"2020","unstructured":"Rampersad C, Whitlock RH, Leslie WD, Rigatto C, Komenda P, Bohm C, Hans D, Tangri N (2020) Trabecular bone score in patients with chronic kidney disease. Osteoporos Int 31:1905\u20131912","journal-title":"Osteoporos Int"},{"key":"7696_CR34","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.mayocp.2016.10.009","volume":"92","author":"F Cosman","year":"2017","unstructured":"Cosman F, Miller PD, Williams GC et al (2017) Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial. Mayo Clin Proc 92:200\u2013210","journal-title":"Mayo Clin Proc"},{"key":"7696_CR35","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.bone.2018.10.020","volume":"120","author":"F Cosman","year":"2019","unstructured":"Cosman F, Nieves JW, Roimisher C, Neubort S, McMahon DJ, Dempster DW, Lindsay R (2019) Administration of teriparatide for four years cyclically compared to two years daily in treatment Naive and alendronate treated women. Bone 120:246\u2013253","journal-title":"Bone"},{"key":"7696_CR36","doi-asserted-by":"publisher","first-page":"e1528","DOI":"10.1210\/clinem\/dgab850","volume":"107","author":"E Shane","year":"2022","unstructured":"Shane E, Shiau S, Recker RR, Lappe JM, Agarwal S, Kamanda-Kosseh M, Bucovsky M, Stubby J, Cohen A (2022) Denosumab after teriparatide in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 107:e1528\u2013e1540","journal-title":"J Clin Endocrinol Metab"},{"key":"7696_CR37","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155","journal-title":"Lancet"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07696-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07696-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07696-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T12:31:59Z","timestamp":1763382719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07696-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["7696"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07696-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2025,9,20]]},"assertion":[{"value":"25 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Dash declares no competing financial interests. Dr. Hind has a relationship with Medimaps Group (consultant or advisory fees). Dr. Hans is the owner of the TBS patent and has a relationship with Medimaps Group (CEO, equity or stocks, board membership). Dr. Nieves reports relationships with Radius Health Inc (funding grants). Dr. Cosman has relationships with Radius Health Inc (consultant or advisory fees, speaker fees), Amgen Inc. (consultant or advisory fees, speaker fees), EnteraBio Ltd (consultant or advisory fees), CuraTeQ Biologics (consultant or advisory fees), Theramex (consultant or advisory fees), and UCB Inc. (consultant or advisory fees).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}